Ирска - Енглески - HPRA (Health Products Regulatory Authority)

octapharma (ip) sprl - human factor viii; von willebrand factor human - powder and solvent for solution for injection - 1000/1000 international unit(s) - blood coagulation factors; von willebrand factor and coagulation factor viii in combination

Израел - Енглески - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - powder and solvent for solution for injection - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii - von willebrand disease (vwd) :prevention and treatment of haemorrhage or surgical bleeding in von willebrand disease (vwd), when desmopressin (ddavp) treatment alone is ineffective or contra-indicated.haemophilia a :treatment and prophylaxis of bleeding in patients with haemophilia a (congenital fviii deficiency).

Израел - Енглески - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - powder and solvent for solution for injection - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii - von willebrand disease (vwd) :prevention and treatment of haemorrhage or surgical bleeding in von willebrand disease (vwd), when desmopressin (ddavp) treatment alone is ineffective or contra-indicated.haemophilia a :treatment and prophylaxis of bleeding in patients with haemophilia a (congenital fviii deficiency).

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

csl behring llc - coagulation factor ix human (unii: 6u90y1795t) (coagulation factor ix human - unii:6u90y1795t) - coagulation factor ix human 500 [iu] in 5 ml - mononine is indicated for the prevention and control of bleeding in factor ix deficiency, also known as hemophilia b or christmas disease. mononine is not indicated in the treatment or prophylaxis of hemophilia a patients with inhibitors to factor viii. mononine contains non-detectable levels of factors ii, vii and x (<0.0025 iu per factor ix unit using standard coagulation assays) and is, therefore, not indicated for replacement therapy of these clotting factors. mononine is also not indicated in the treatment or reversal of coumarin-induced anticoagulation or in a hemorrhagic state caused by hepatitis-induced lack of production of liver dependent coagulation factors. known hypersensitivity to mouse protein is a contraindication to mononine.

Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

csl behring gmbh - human blood coagulation factor viii, human von willebrand factor (vwf:rco) - powder and solvent for solution for injection/ infusion - 1000iu+ 2400iu

Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

csl behring gmbh - human blood coagulation factor viii, human von willebrand factor (vwf:rco) - powder and solvent for solution for injection/ infusion - 500iu+ 1200iu

Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

csl behring gmbh - human blood coagulation factor viii, human von willebrand factor (vwf:rco) - powder and solvent for solution for injection/ infusion - 250iu+ 600iu

Израел - Енглески - Ministry of Health

takeda israel ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for injection/infusion - factor viii inhibitor bypassing fraction 500 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors.control of bleeding in hemophilia b patients with inhibitors, if no other specific treatment is available.

Израел - Енглески - Ministry of Health

takeda israel ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for injection/infusion - factor viii inhibitor bypassing fraction 1000 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors .control of bleeding in hemophilia b patients with inhibitors, if no other specific treatment is available.

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

octapharma limited - factor viii (antihaemophilic factor), von willebrand factor human - pdr+solv for soln for inj - 1000/1000 international unit - blood coagulation factors